|
O.A. Polyakova, L.D. Kozgunova, O.D. Ostroumova
Metabolically associated fatty liver disease: the role of ademetionine
|
№1-2 / 2023
|
|
I.V. Maev, MD, T.E. Polunina
Medicines And Liver
|
№2 / 2013
|
|
A.N. Kazyulin, L.Z. Velsher, N.N. Danilevskaya, E. A.Mayevskaya
Drug-induced Hepatotoxicity During Chemotherapy For Oncological Diseases And Potentials For Its Correction
|
№8 / 2012
|
|
Polunina T.E.
Strategy For Diagnosis And Treatment Of Alcoholic Liver Disease
|
№7 / 2012
|
|
L.A. Zvenigorodskaya
Lipid-lowering Therapy In Patients With Nonalcoholic Fatty Liver Disease
|
№10 / 2011
|
|
Pticina S.N.
Unique Role Of Ademetionine In Cell Metabolism And Its Pharmacological Potential
|
№20 / 2010
|
|
A.N. Kazyulin, L.Z. Vel’cher, I.A. Koroleva
Hepatotoxicity During Anticancer Chemotherapy Of Oncological Diseases And Methods Of Its Correction
|
№17 / 2010
|
|
Ye.V.Golovanova
Experience Of Use Of Native Hepatoprotector Heptor (ademetionine) In Patients With Alcoholic Liver Disease
|
№12 / 2010
|
|
S.V. Kikta, M.JU. Drobizhev, T.A. Belousova
Depressions In Patients With Psoriasis
|
№11 / 2010
|
|
Snegovoi A.V., Manzuk L.V.
Efficaсy of Heptral® in treatment of hepatotoxicity, induced by chemotherapy
|
№6 / 2010
|
|
A.A. Jakovlev, S.I. Kotljarov
Possibilities Of Objective Improvement Of The Results Of Chronic Viral Hepatitis Therapy With The Drug Heptral
|
№8 / 2009
|
Русский
